Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENVB NASDAQ:GNPX NASDAQ:OBSV NASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENVBEnveric Biosciences$2.29-0.4%$2.60$1.71▼$17.64$8.46M1.122.53 million shs39,284 shsGNPXGenprex$0.75-3.4%$1.18$0.72▼$55.00$7.97M-0.98931,129 shs348,325 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs1,945 shsSBFMSunshine Biopharma$2.42-5.0%$0.87$2.11▼$24.30$12.10M1.13807,817 shs396,771 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENVBEnveric Biosciences0.00%+4.07%-41.77%+2.22%-83.62%GNPXGenprex0.00%-5.07%-20.05%-60.83%-95.61%OBSVObsEva0.00%0.00%0.00%+400.00%-50.00%SBFMSunshine Biopharma0.00%-47.21%-73.59%-78.09%-81.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENVBEnveric Biosciences$2.29-0.4%$2.60$1.71▼$17.64$8.46M1.122.53 million shs39,284 shsGNPXGenprex$0.75-3.4%$1.18$0.72▼$55.00$7.97M-0.98931,129 shs348,325 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs1,945 shsSBFMSunshine Biopharma$2.42-5.0%$0.87$2.11▼$24.30$12.10M1.13807,817 shs396,771 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENVBEnveric Biosciences0.00%+4.07%-41.77%+2.22%-83.62%GNPXGenprex0.00%-5.07%-20.05%-60.83%-95.61%OBSVObsEva0.00%0.00%0.00%+400.00%-50.00%SBFMSunshine Biopharma0.00%-47.21%-73.59%-78.09%-81.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENVBEnveric Biosciences 1.00SellN/AN/AGNPXGenprex 1.00SellN/AN/AOBSVObsEva 0.00N/AN/AN/ASBFMSunshine Biopharma 2.00Hold$70.002,798.55% UpsideCurrent Analyst Ratings BreakdownLatest SBFM, GNPX, ENVB, and OBSV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026SBFMSunshine Biopharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/21/2026ENVBEnveric Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SBFMSunshine Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENVBEnveric BiosciencesN/AN/AN/AN/A$7.00 per shareN/AGNPXGenprexN/AN/AN/AN/A$2.42 per shareN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ASBFMSunshine Biopharma$36.31M0.33N/AN/A$4.69 per share0.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENVBEnveric Biosciences-$8.77M-$23.54N/AN/AN/AN/A-220.97%-177.47%8/17/2026 (Estimated)GNPXGenprex-$16.23M-$14.14N/AN/AN/AN/A-247.32%-176.73%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ASBFMSunshine Biopharma-$5.97M-$1.29N/AN/AN/A-18.45%-27.75%-21.57%8/11/2026 (Estimated)Latest SBFM, GNPX, ENVB, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ENVBEnveric BiosciencesN/A-$1.08N/A-$1.08N/AN/A5/13/2026Q1 2026GNPXGenprexN/A-$0.64N/A-$0.64N/AN/A5/13/2026Q1 2026SBFMSunshine Biopharma-$1.60-$2.50-$0.90-$0.25$9.20 million$8.09 million4/3/2026Q4 2025SBFMSunshine Biopharma-$2.70-$4.60-$1.90-$0.46$10.00 million$8.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENVBEnveric BiosciencesN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENVBEnveric BiosciencesN/A11.6611.66GNPXGenprexN/A5.615.61OBSVObsEvaN/A0.610.61SBFMSunshine BiopharmaN/A4.221.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENVBEnveric Biosciences13.82%GNPXGenprex14.05%OBSVObsEva17.52%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipENVBEnveric Biosciences2.41%GNPXGenprex0.25%OBSVObsEva14.40%SBFMSunshine Biopharma0.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENVBEnveric Biosciences203.68 million3.59 millionNot OptionableGNPXGenprex2010.59 million10.56 millionNo DataOBSVObsEva5077.97 million66.74 millionNot OptionableSBFMSunshine Biopharma35.01 million5.00 millionNot OptionableSBFM, GNPX, ENVB, and OBSV HeadlinesRecent News About These CompaniesSunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)June 1 at 8:00 AM | accessnewswire.comASunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment TechnologyMay 29 at 8:00 AM | accessnewswire.comASunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Up 376.4% in MayMay 29 at 1:43 AM | americanbankingnews.comSunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ ListingMay 28, 2026 | accessnewswire.comASunshine Biopharma Receives Canadian Regulatory Approval for Generic AmoxicillinMay 21, 2026 | accessnewswire.comASunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public OfferingMay 19, 2026 | accessnewswire.comASunshine Biopharma Inc. Announces Pricing of $6.0 Million Public OfferingMay 18, 2026 | accessnewswire.comASBFM Share News TodayMay 15, 2026 | uk.investing.comSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comSunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior YearApril 6, 2026 | accessnewswire.comASunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)October 28, 2025 | accessnewswire.comASunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comSunshine Biopharma stock rises after Health Canada approval for DomperidoneOctober 28, 2025 | za.investing.comSunshine Biopharma Inc.: Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | finanznachrichten.deSunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 21, 2025 | finanznachrichten.deSunshine Biopharma announces commercial launch of doxycycline in CanadaOctober 20, 2025 | msn.comSunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 20, 2025 | accessnewswire.comASunshine Biopharma stock soars after launch of cholesterol drug PravastatinOctober 16, 2025 | au.investing.comSunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian UnitOctober 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBFM, GNPX, ENVB, and OBSV Company DescriptionsEnveric Biosciences NASDAQ:ENVB$2.29 -0.01 (-0.43%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Genprex NASDAQ:GNPX$0.75 -0.03 (-3.40%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Sunshine Biopharma NASDAQ:SBFM$2.42 -0.13 (-4.96%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
